Save

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)

PHASE3RECRUITING

This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug combinations and intravenous prostacyclin. The primary objective of this open-label, LTFU study is to evaluate the long-term safety and tolerability of sotatercept when added to background PAH therapy in adult participants with PAH who have completed prior sotatercept studies.

The secondary objective is to evaluate continued efficacy in adult participants with PAH who have completed prior sotatercept studies.

Simpliy with AI

Study details:

Participants eligible to enroll in the study will have participated in and completed the relevant study requirements of the parent PAH sotatercept clinical studies.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Have completed their current respective PAH sotatercept clinical study and its requirements, and must not have discontinued early

Must be willing to adhere to the study visit schedule and understand and comply with all protocol requirements

Must have the ability to understand and provide documented informed consent

Females of childbearing potential must:

Have a negative pregnancy test as verified by the investigator prior to starting study drug administration; she must agree to ongoing pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug

If sexually active, have used, and agree to continue to use highly effective contraception in combination with a barrier method without interruption, for at least 28 days prior to starting the investigational product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study drug

Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study drug

Male participants must:

Agree to use a condom, defined as a male latex condom or non latex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy

Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study drug

Must agree not to participate in any other trials of investigational drugs/devices while they are enrolled in the MK-7962-004 study

Exclusion criteria

Did not participate in a sotatercept PAH parent trial

Missed more than the equivalent of 4 consecutive doses between the end of parent study and the start of this study.

Presence of an ongoing serious adverse event (SAE) that occurred during a PAH sotatercept clinical study that is assessed to be possibly or probably related to sotatercept

Pregnant or breastfeeding females

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2021-05-12

Primary completion: 2027-09-30

Study completion finish: 2027-11-30

Study type

TREATMENT

Phase

PHASE3

Trial ID

NCT04796337

Intervention or treatment

BIOLOGICAL: Sotatercept

Conditions

• Pulmonary Arterial Hypertension
• PAH

Image related to Pulmonary Arterial Hypertension

Condition: Pulmonary Arterial Hypertension, PAH
BIOLOGICAL: Sotatercept
Camperdown, New South Wales, Australia and more
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Royal Prince Alfred Hospital ( Site 1106)

Research sites nearby

Select from list below to view details:

Royal Prince Alfred Hospital ( Site 1106)
Camperdown, New South Wales, Australia
Princess Alexandra Hospital ( Site 1108)
Woolloongabba, Queensland, Australia
Royal Adelaide Hospital ( Site 1109)
Adelaide, South Australia, Australia
Royal Hobart Hospital ( Site 1107)
Hobart, Tasmania, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Sotatercept Treatment Participants rolling over from a blinded parent study will begin sotatercept at a dose of 0.3 mg/kg SC for Visit 1. Dose will escalate to 0.7 mg/kg SC at Visit 2 through remainder of the study. Participants rolling over from an unblinded parent study will continue sotatercept at their current dose and if at dose \< 0.7 mg/kg SC can titrate up to 0.7 mg/kg SC for the remainder of the study.	BIOLOGICAL: Sotatercept Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.

Participant Group/Arm

Intervention/Treatment

EXPERIMENTAL: Sotatercept Treatment

Participants rolling over from a blinded parent study will begin sotatercept at a dose of 0.3 mg/kg SC for Visit 1. Dose will escalate to 0.7 mg/kg SC at Visit 2 through remainder of the study. Participants rolling over from an unblinded parent study will continue sotatercept at their current dose and if at dose \< 0.7 mg/kg SC can titrate up to 0.7 mg/kg SC for the remainder of the study.

BIOLOGICAL: Sotatercept

Sotatercept subcutaneous injection at a dose of 0.3 to 0.7 mg/kg.

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Number of Participants Who Experience an Adverse Event (AE)	AE is any untoward medical occurrence in a clinical investigation participant administered a study drug, which does not necessarily have a causal relationship with this treatment. The number of participants who experience an AE will be reported.	Up to approximately 50 months
Number of Participants Who Discontinue Study Treatment Due to an AE	AE is any untoward medical occurrence in a clinical investigation participant administered a study drug, which does not necessarily have a causal relationship with this treatment. The number of participants who discontinue study treatment due to an AE will be reported.	Up to approximately 50 months
Number of Participants with Detectable Anti-Drug Antibodies (ADAs)	ADAs will be detected in serum. The number of participants with detectable ADAs will be presented.	Up to approximately 50 months
Laboratory parameters (Hematology): Concentration of Red Blood Cell Count, White Blood Cell Count, Platelet Count, Hemoglobin and Hematocrit	Blood samples will be collected to determine concentration of red blood cell count, white blood cell count, platelet count, hemoglobin and hematocrit at designated timepoints up to approximately 50 months.	Up to approximately 50 months
Laboratory parameters (Serum Chemistry): Concentration of Blood Urea, Creatinine, Total Bilirubin, Direct Bilirubin, AST, ALT, ALP, Sodium, Potassium, Chloride, Calcium, Phosphorous, Glucose, Magnesium, Carbon Dioxide, and Albumin	Blood samples will be collected to determine concentration of blood urea, creatinine, total bilirubin, direct bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP, sodium, potassium, chloride, calcium, phosphorous, glucose, magnesium, carbon dioxide, and albumin at designated time points for up to approximately 50 months.	Up to approximately 50 months
Laboratory parameter: Concentration of Follicle Stimulating Hormone (FSH)	Blood samples will be collected to determine concentration of FSH level at designated time points up to approximately 50 months.	Up to approximately 50 months
Change From Baseline in Body Weight	Change from baseline in body weight will be reported at designated time points up to approximately 48 months.	Baseline and up to approximately 48 months
Change From Baseline in Blood Pressure	Change from baseline in systolic and diastolic blood pressure will be reported at designated time points up to approximately 48 months.	Baseline and up to approximately 48 months
Change From Baseline in Electrocardiogram (ECG)	Change from baseline in ECG (12-lead) for the determination of QTcF interval will be reported at designated time points up to approximately 48 months.	Baseline and up to approximately 48 months
Laboratory parameters (Urinalysis): pH, Specific Gravity, Protein, Glucose, Bilirubin, Ketones, Blood, Leukocyte Esterase, Urobilinogen, and Nitrite	Urine samples will be collected to determine pH, specific gravity, protein, glucose, bilirubin, ketones, blood, leukocyte esterase, urobilinogen, and nitrite at designated timepoints up to approximately 48 months.	Up to approximately 48 months

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Change From Baseline in 6-Minute Walk Distance (6MWD)	The 6MWD was the distance walked in 6 minutes as a measure of functional capacity. This was assessed using the 6-minute walk test (6MWT). The change from baseline in 6MWD will be reported.	Baseline and up to approximately 48 months
Change From Baseline in N-Terminal Pro-Hormone B-type Natriuretic Peptide (NT-proBNP) Levels	NT-proBNP is a circulating biomarker that reflects myocardial stretch. The change from baseline in NT-proBNP level will be reported.	Baseline and up to approximately 48 months
Change From Baseline in the Percentage of Participants Who Improve in modified New York Heart Association (NYHA)/ World Health Organization classification of functional status (WHO FC)	The severity of participant's pulmonary arterial hypertension (PAH) symptoms will be graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity) and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change" and "Worsened". Improvement = reduction in FC, worsened = increase in FC and no change = no change in FC. The change from baseline in the percentage of participants who improve in WHO FC will be reported.	Baseline and up to approximately 48 months
Change From Baseline in Pulmonary Vascular Resistance (PVR)	PVR is a hemodynamic variable of pulmonary circulation and was measured by right heart catheterization (RHC). The change from baseline in PVR will be reported.	Baseline and up to approximately 48 months
Overall Survival (OS)	Overall survival is defined as the time from the start of the first sotatercept treatment in the individual participant's parent study or in this study, if the participant was completely on placebo in the parent study, to the date of death in this study, regardless of the actual cause of the participant's death.	Up to approximately 78 months
Change From Baseline in Percentage of Participants Who Maintain or Achieve a Low Risk Score Using the Simplified French Risk Score Calculator	The simplified French risk scoring system was based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of pulmonary hypertension (PH). In this study, the noninvasive parameters were used to determine the score. 'Low risk' was defined as attaining or maintaining all 3 low-risk criteria: WHO FC I or II, 6MWD \> 440 m, and NT-proBNP \<300 ng/L. The change from baseline in percentage of participants who maintained or achieved a low risk score using the simplified French risk score calculator will be reported.	Baseline and up to approximately 48 months
Change From Baseline in Borg Dyspnea Scale Category Ratio 10 (Borg CR 10) Score	The Borg CR 10 Scale assesses the severity of shortness of breath as perceived by the participant. Participants will be asked: How much difficulty is your breathing causing you right now?". The score of the item ranges from 0 (no difficulty in breathing) to10 (maximum difficulty in breathing). Higher score indicates more severe dyspnea. The change from baseline in Borg CR10 scale score will be reported.	Baseline and up to approximately 48 months

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)